AstraZeneca’s win in lung cancer; Sandoz inks a China deal

Data ReadoutpositiveTagrissoOrpathysPositive

AI Analysis

Summary

AstraZeneca's Tagrisso combined with Hutchmed's Orpathys demonstrated extended survival in lung cancer patients. Sandoz inked a China deal and MapLight is seeking a partner for its autism drug.

Outcome Details

combination of Tagrisso and Orpathys extended survival for some lung cancer patients

Importance:6/10

Sentiment:

0.70

lung cancercombination therapysurvival benefitpartnership

Related Companies

$AZN $HMDCF $SDZ.SW

Read the original article

Published by BioPharma Dive on August 18, 2026 3:13 PM

Read Original